United Kingdom Bronchodilators Market to be Dominated by Asthma & Chronic Obstructive Pulmonary Disease (COPD) through 2028
The increasing concern about
chronic obstructive pulmonary disease is expected to drive the growth of United
Kingdom bronchodilators market in the forecast period, 2024-2028.
According to TechSci Research
report, “United Kingdom Bronchodilators Market - By Region, Competition,
Forecast and Opportunities, 2028”, United Kingdom bronchodilators market is
anticipated to grow at an impressive rate in the forecast period, 2024-2028.
It can be ascribed to the rising demand for beta-2 agonists with medical
benefits such as bronchodilation, rapid symptom relief, prevention of
exercise-induced bronchoconstriction, and maintenance therapy along with growing
preference for long-acting bronchodilators among people with Asthma & COPD
related issues across the region. Additionally, rapid advances in science and
technology, increasing healthcare expenditure, changes in habits (smoking),
burgeoning aging population, and rising interest in attaining wellness through
bronchodilators will escalate the growth of United Kingdom bronchodilators
market in coming years. Besides, emergence of new fixed-dose combination
inhalers, digital inhaler devices, improved inhaler techniques, and generic
versions of bronchodilators will be expected to support the United Kingdom
bronchodilators market growth.
In the United Kingdom, however,
bronchodilator regulation is complicated and there are regulatory bodies such
as the MHRA that looks after stringent regulatory requirements and procedures
that can create barriers for new entrants and lead to delays in bringing
innovative bronchodilator products to the market. It can slow the growth of
United Kingdom bronchodilators market in the forecast period. Similarly, there
is patent expirations of branded bronchodilators that can result in the entry
of generic versions and hamper the United Kingdom bronchodilators market growth
during the forecast period. Also, there is a growing focus on
non-pharmacological interventions and holistic approaches to respiratory health
management. It includes lifestyle modifications, respiratory therapy, pulmonary
rehabilitation, and alternative therapies which can further restrict the growth
of United Kingdom bronchodilators market.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on "United Kingdom Bronchodilators Market.”
The United Kingdom
Bronchodilators market can be segmented by type, indication, route of
administration, and region.
Based on type, the United Kingdom
bronchodilators market can be segmented into beta-adrenergic bronchodilators,
anticholinergic bronchodilators, xanthine derivatives, and others. The
beta-adrenergic bronchodilators segment dominated the market in 2022 and is
expected to continue maintaining its dominance throughout the forecast period.
This can be ascribed to increasing demand for bronchodilators for the treatment
of respiratory conditions such as Asthma and COPD. They work by stimulating
beta receptors in the airway muscles, resulting in bronchodilation.
Beta-agonists can be further categorized into short-acting (SABAs) and
long-acting (LABAs) forms.
Based on Indication, the market
can be segmented into Asthma, chronic obstructive pulmonary disease (COPD), and
others. The Asthma & Chronic Obstructive Pulmonary Disease (COPD) segment
is expected to dominate during the forecast period on account of the rising
awareness related to the Asthma is a chronic respiratory condition
characterized by inflammation and narrowing of the airways. Bronchodilators
play a crucial role in managing asthma symptoms and improving airflow &
COPD is a progressive respiratory disease that includes conditions such as
chronic bronchitis and emphysema. Bronchodilators are a cornerstone of COPD
treatment, aiming to reduce symptoms and improve lung function.
Major companies operating in United Kingdom
bronchodilators market are:
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Novartis AG
- Teva Pharmaceutical Industries
Ltd.
- Cipla EU Ltd
- Sunovion Pharmaceuticals Ltd
- GlaxoSmithKline Inc/United
Kingdom
In 2020, Novartis AG acquired The
Medicine Company at USD 85.00 per share to use vaccine-like strategy for
treating the Asthma & COPD biggest cause of death and disability in the
world. It represents a huge advancement in our efforts to refocus the business,
rethink medicine, and alter the course of human history.
In 2020, AstraZeneca acquired
Alexion pharmaceuticals in USD 60 million in cash and 2.1243 AstraZeneca
American Depositary shares (ADSs). To encourage future medical innovation, the
combined companies will bring together two patient-centric models of care
delivery that are quickly convergent and have complementary capabilities in
immunology, biologics, genomics, and oligonucleotides.
In January 2023, AstraZeneca
acquired Cincor’s a transaction value of approximately $1.8 Bn and a 206%
premium over CinCor’s closing market price on 6 January 2023. It develops novel
treatments for unaffected and uncontrolled hypertension as well as chronic
kidney disease.
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“United Kingdom bronchodilators
is expected to dominate the market during the forecast period on account of the
rising demand for beta-2 agonists with medical benefits along with growing
preference for personalized medical device in the region. Furthermore, trend of
inhaler device technology advancements is growing, particularly among
individuals with Asthma & COPD-related medical conditions, where generic
treatment is short-acting bronchodilators, long-acting bronchodilators, and
Inhaled corticosteroids (ICS) which will further contributing to demand for
United Kingdom bronchodilators market during the forecast period. Besides,
increasing concern about healthy lifestyles and increasing expenditure on
health and wellness is further expected to create lucrative opportunities for
the market growth” said Mr. Karan Chechi, Research Director with TechSci
Research, a research based global management consulting firm.
“United Kingdom
Bronchodilators Market by Type (Beta-Adrenergic Bronchodilators,
Anticholinergic Bronchodilators, Xanthine Derivatives, Others), By Indication
(Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others), By Route of
Administration (Oral, Nasal, Injectable) and By Region and Competition”,
has evaluated the future growth potential of United Kingdom Bronchodilators
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United Kingdom Bronchodilators
Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com